BofA analyst Tazeen Ahmad downgraded Fate Therapeutics to Underperform from Buy with a price target of $4, down from $72.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FATE:
- Fate Therapeutics downgraded to Neutral from Outperform at Wedbush
- Fate Therapeutics downgraded to Hold from Buy at Stifel
- Here’s Why Fate Therapeutics (NASDAQ:FATE) Stock Is Sliding Down
- Fate Therapeutics downgraded on lack of catalysts at Cowen
- Fate Therapeutics downgraded to Market Perform from Outperform at Cowen